BioCancell To Raise $2.6M To Fund Bladder Cancer Treatment Trial

January 7, 2014 | Six weeks following its decision to suspend development of its flagship drug for treatment of pancreatic cancer, Israeli biomed company BioCancell is planning to raise up to NIS 9 million (approx. $2.57 million) in a rights issue. The funds will be directed towards the Phase III trial of the company’s treatment for bladder cancer. TheMarker reports that The company estimates that the funds should be sufficient for maintaining operation at least through Q3 2014.